Denali Therapeutics Inc. (NASDAQ:DNLI) went up by 11.92% from its latest closing price compared to the recent 1-year high of $79.70. The company’s stock price has collected 21.26% of gains in the last five trading sessions.
Is It Worth Investing in Denali Therapeutics Inc. (NASDAQ :DNLI) Right Now?
Plus, the 36-month beta value for DNLI is at 1.83. Opinions of the stock are interesting as 10 analysts out of 13 who provided ratings for Denali Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $71.55, which is $47.25 above the current price. DNLI currently public float of 97.64M and currently shorts hold a 7.98% ratio of that float. Today, the average trading volume of DNLI was 572.05K shares.
DNLI’s Market Performance
DNLI stocks went up by 21.26% for the week, with a monthly jump of 12.54% and a quarterly performance of -19.77%, while its annual performance rate touched -63.22%. The volatility ratio for the week stands at 9.02% while the volatility levels for the past 30 days are set at 7.43% for Denali Therapeutics Inc. The simple moving average for the period of the last 20 days is 13.00% for DNLI stocks with a simple moving average of -29.63% for the last 200 days.
Analysts’ Opinion of DNLI
Oppenheimer, on the other hand, stated in their research note that they expect to see DNLI reach a price target of $85. The rating they have provided for DNLI stocks is “Outperform” according to the report published on September 21st, 2021.
SMBC Nikko gave a rating of “Outperform” to DNLI, setting the target price at $78 in the report published on September 01st of the previous year.
DNLI Trading at 6.69% from the 50-Day Moving Average
After a stumble in the market that brought DNLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.44% of loss for the given period.
Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 9.02%, as shares surge +8.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.93% lower at present.
During the last 5 trading sessions, DNLI rose by +21.26%, which changed the moving average for the period of 200-days by -52.21% in comparison to the 20-day moving average, which settled at $23.77. In addition, Denali Therapeutics Inc. saw -40.02% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at DNLI starting from Tessier-Lavigne Marc, who sale 20,000 shares at the price of $33.83 back on Mar 23. After this action, Tessier-Lavigne Marc now owns 2,024,370 shares of Denali Therapeutics Inc., valued at $676,583 using the latest closing price.
Watts Ryan J., the President and CEO of Denali Therapeutics Inc., sale 9,491 shares at $34.72 during a trade that took place back on Feb 11, which means that Watts Ryan J. is holding 2,129,648 shares at $329,528 based on the most recent closing price.
Stock Fundamentals for DNLI
Current profitability levels for the company are sitting at:
- -607.78 for the present operating margin
- +88.47 for the gross margin
The net margin for Denali Therapeutics Inc. stands at -597.15. Equity return is now at value -28.80, with -20.10 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.37.